sphingotec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...
COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY
A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS